131 related articles for article (PubMed ID: 38357171)
21. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
23. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
26. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
27. Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.
Tangjitgamol S; Tanvanich S; Srijaipracharoen S; Manusirivithaya S
Histol Histopathol; 2013 Jun; 28(6):787-94. PubMed ID: 23255089
[TBL] [Abstract][Full Text] [Related]
28. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
Liu N; Wang X; Sheng X
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
[TBL] [Abstract][Full Text] [Related]
29. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
30. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
[TBL] [Abstract][Full Text] [Related]
32. Frequency of distribution of oestrogen and progesterone receptors positivities in breast cancer cases in Benin-City, Nigeria.
Ugiagbe EE; Obaseki DE; Oluwasola AO; Olu-Eddo AN; Akhiwu WO
Niger Postgrad Med J; 2012 Mar; 19(1):19-24. PubMed ID: 22430597
[TBL] [Abstract][Full Text] [Related]
33. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
34. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
35. Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Verma D; Agarwal K; Tudu SK
Indian J Pathol Microbiol; 2018; 61(1):31-38. PubMed ID: 29567881
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
37. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
38. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
40. Estrogen and progesterone receptors in ovarian cancer.
Harding M; Cowan S; Hole D; Cassidy L; Kitchener H; Davis J; Leake R
Cancer; 1990 Feb; 65(3):486-91. PubMed ID: 2297640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]